Literature DB >> 3812616

Intraoperative argon endophotocoagulation for recurrent vitreous hemorrhage after vitrectomy for diabetic retinopathy.

P E Liggett, J S Lean, W E Barlow, S J Ryan.   

Abstract

We reviewed the medical records of 103 consecutive cases of vitrectomy performed for complications of diabetic retinopathy to determine if the introduction of argon laser endophotocoagulation had reduced the incidence of recurrent vitreous hemorrhage. Twenty-six eyes (48%) treated with endophotocoagulation and 35 (71%) eyes not receiving laser treatment had a recurrent hemorrhage. Follow-up was shorter for the eyes treated with endophotocoagulation, but a log-rank analysis to allow for this variable confirmed the benefit of laser photocoagulation (P less than .05). The proportion of eyes requiring surgical removal of the hemorrhage was also significantly lower in the group receiving endophotocoagulation (P less than .05). The beneficial effect of intraoperative laser treatment was independent of the amount of preoperative laser treatment, aphakia, and indications for the original vitrectomy surgery.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3812616     DOI: 10.1016/s0002-9394(14)74219-9

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  7 in total

1.  Long-term visual and retinopathy outcomes in a predominately type 2 diabetic patient population undergoing early vitrectomy and endolaser for severe vitreous haemorrhage.

Authors:  G Ratnarajan; F Mellington; M Saldanha; S R de Silva; L Benjamin
Journal:  Eye (Lond)       Date:  2011-04-15       Impact factor: 3.775

2.  Perfluorocarbon in vitreoretinal surgery and preoperative bevacizumab in diabetic tractional retinal detachment.

Authors:  J Fernando Arevalo; Martin A Serrano; Juan D Arias
Journal:  World J Diabetes       Date:  2014-10-15

Review 3.  Current management of vitreous hemorrhage due to proliferative diabetic retinopathy.

Authors:  Jaafar El Annan; Petros E Carvounis
Journal:  Int Ophthalmol Clin       Date:  2014

4.  Six-month visual outcome after pars plana vitrectomy in proliferative diabetic retinopathy with or without a single preoperative injection of intravitreal bevacizumab.

Authors:  Amod Gupta; Reema Bansal; Vishali Gupta; Mangat R Dogra
Journal:  Int Ophthalmol       Date:  2012-03-27       Impact factor: 2.031

5.  Intravitreal bevacizumab as an adjunctive therapy before diabetic vitrectomy.

Authors:  Ashraf M El-Batarny
Journal:  Clin Ophthalmol       Date:  2008-12

6.  Encircling panretinal laser photocoagulation may prevent macular detachment after vitrectomy for proliferative diabetic retinopathy.

Authors:  H L Hudson; L P Chong; D A Frambach; M Valencia; R L Green; P F Lopez
Journal:  Int Ophthalmol       Date:  1994       Impact factor: 2.031

Review 7.  Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy.

Authors:  Jonathan M Smith; David H W Steel
Journal:  Cochrane Database Syst Rev       Date:  2015-08-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.